Automated risk stratification in localized prostate cancer using an AI-assisted framework.

U Umair Ayub (1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States) S Syed Arsalan Ahmed Naqvi (Mayo Clinic, Phoenix, AZ) S Salman Ayub Jajja (NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States) M Muhammad Umar Afzal (Mayo Clinic Arizona, Scottsdale, AZ) K Kaneez Zahra Rubab Khakwani (University of Arizona, Tucson, AZ) J Jack Andrews (Mayo Clinic Arizona, Phoenix, AZ) A Alan Haruo Bryce (Mayo Clinic Arizona, Phoenix, AZ) A Alton Oliver Sartor (LCMC Health, New Orleans, LA) H Haidar Abdul-Muhsin (Mayo Clinic Arizona, Phoenix, AZ) D Daniel S Childs (Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN) J Jacob Orme (Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN) C Chitta Baral (Arizona State Univeristy (ASU), Tempe, AZ) N Neeraj Agarwal (Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA) S Sumanta Kumar Pal (Department of Medical Oncology City of Hope Comprehensive Cancer Center Duarte California USA) A Abhishek Tripathi (Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte California USA) P Parminder Singh (Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ) Y Yousef Zakharia (Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA) I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA)

Abstract

341 Background: Specialist clinicians (oncologists, urologists, radiation oncologists) read through free text reports of prostate MRI and biopsy reports to risk stratify patients during initial consultation of localized PCa. This laborious and time-consuming process is repeated for each day during the clinic. Herein, we propose a hybrid stratification framework utilizing a combination of large language model (LLM) and rule-based programming to automate this process. Methods: This retrospective study included patients with localized PCa (2004-2024) presenting to care at Mayo Clinic with at least one positive prostate biopsy and MRI report available. The state-of-the-art LLM – GPT4 – was utilized using a structured zeroshot prompt to extract relevant phenotypic variables (clinical T stage, Gleason patterns, grade group, extent of specimen/cores involved, prostate size/volume) from unstructured MRI and biopsy reports. Using a rule-based algorithm, the extracted variables and PSA at PCa diagnosis were used to categorize each patient into one of the six NCCN risk categories (very low [VL], low [L], favorable intermediate [FInt], unfavorable intermediate [UFInt], high risk (HR), very high risk [VHR]). Prompts were iteratively developed using ~5% of the total dataset and validated on ~10% of the dataset. Final performance was assessed against a held-out expert annotated test dataset using evaluation metrics (accuracy, F1-score, precision, recall). Additionally, manual annotation was conducted by two independent novice reviewers to compare machine annotated and novice-human annotated risk categorization. Results: A total of 397 patients were included in the evaluation. The median age at diagnosis was 64.8 (IQR: 59.7-68.5); majority of the men were White (n: 366; 92%) and non-Hispanic (n: 371; 94%). The most prevalent risk category was UFint (n: 151; 38%) followed by FInt (n: 80; 20.2%), HR (n: 76; 19.1%), VHR (n: 64; 16.1%), L (21: 5.3%), and VL (n: 5; 1.3%). Novice reviewers achieved an accuracy of 79%, precision of 80%, recall of 82% and a F1-score of 0.81. The hybrid stratification framework using GPT4 achieved an accuracy of 89%, precision of 89%, recall of 88% and a F1-score of 0.88. Among 43 errors by GPT4 risk stratification, majority of the errors were due to miscategorization of clinical T-stage (n: 21; 49%) followed by erroneous number of positive cores (n: 13; 30%). However, additional evaluation showed that GPT4 achieved numerically higher performance (accuracy: 90%; precision: 91%; recall: 90%; F1: 0.90) compared to novice reviewers (accuracy: 77%; precision: 89%; recall: 77%; F1: 0.82) for ascertaining clinical T-stage. Conclusions: Large language models exhibited superior performance than novice clinicians for risk stratification in patients with localized PCa. As the next step, we intend to validate our framework for automated risk classification in a prospective manner.

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 341-341
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (18)

U

Umair Ayub

1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States

S

Syed Arsalan Ahmed Naqvi

Mayo Clinic, Phoenix, AZ

S

Salman Ayub Jajja

NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States

M

Muhammad Umar Afzal

Mayo Clinic Arizona, Scottsdale, AZ

K

Kaneez Zahra Rubab Khakwani

University of Arizona, Tucson, AZ

J

Jack Andrews

Mayo Clinic Arizona, Phoenix, AZ

A

Alan Haruo Bryce

Mayo Clinic Arizona, Phoenix, AZ

A

Alton Oliver Sartor

LCMC Health, New Orleans, LA

H

Haidar Abdul-Muhsin

Mayo Clinic Arizona, Phoenix, AZ

D

Daniel S Childs

Division of Medical Oncology, Mayo Clinic Rochester, Rochester, MN

J

Jacob Orme

Department of Medical Oncology, Mayo Clinic Rochester, Rochester, MN

C

Chitta Baral

Arizona State Univeristy (ASU), Tempe, AZ

N

Neeraj Agarwal

Division of Medical Oncology Department of Internal Medicine Huntsman Cancer Institute University of Utah Salt Lake City Utah USA

S

Sumanta Kumar Pal

Department of Medical Oncology City of Hope Comprehensive Cancer Center Duarte California USA

A

Abhishek Tripathi

Department of Medical Oncology and Therapeutics Research City of Hope Comprehensive Cancer Center Duarte California USA

P

Parminder Singh

Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ

Y

Yousef Zakharia

Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA